[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jefferson Drapkin\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632423","phase-4-pipelle-vs-the-curved-aspirator-device-100632423",false,"NCT07513493","Pipelle vs the Curved Aspirator Device","The Conventional Pipelle vs the Curved Aspirator Device: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients \\\u003C18- 45 years with risk factors for endometrial cancer requiring endometrial biopsy.\n2. Patients ≥ 45 -95 years with abnormal uterine bleeding.\n3. Postmenopausal patients with bleeding or suspected endometrial pathology\n\nExclusion Criteria:\n\n1. Any patient who does not meet the inclusion criteria.\n2. Patients with contraindications to endometrial biopsy, including:\n\n   * Pregnancy\n   * Acute pelvic inflammatory disease\n   * Acute cervical infection\n   * Acute vaginal infection\n   * Cervical cancer\n   * Lack of patient consent",true,"FEMALE","18 Years","95 Years",{"count":21,"type":22},124,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The primary aim of this study is to rigorously compare the efficacy of two commonly used endometrial sampling devices, the Pipelle and the Miltex, these devices are standard of care at Maimonides. This primary objective is critical, as the ability to accurately reach the uterine cavity is fundamental to obtaining adequate samples for histopathological evaluation, which is crucial for diagnosing endometrial cancer and other uterine pathologies.",[28],"Endometrial Biopsy",[30],"Gynecology","RECRUITING","2026-09-14",{"date":34,"type":35},"2026-09-17","ACTUAL",{"date":37,"type":35},"2026-01-02",{"date":39,"type":22},"2028-03-31",{"name":41,"class":42},"Jefferson Drapkin","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100630783","phase-2-efficacy-of-cabergoline-in-inhibiting-lactation-and-alleviating-breast-symptoms-100630783","NCT07492160","Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms After 12-18 Week Abortion or Pregnancy Loss: A Pilot and Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant people aged 18 years or older\n* Gestational age between 12 and 18 weeks\n* Undergoing treatment for spontaneous or induced abortion at Maimonides Medical Center\n* Able to provide informed consent\n* Willing and able to complete study surveys\n\nExclusion Criteria:\n\n* Prior mastectomy\n* Currently breastfeeding\n* Current use of a dopamine agonist or dopamine antagonist medication\n* Known contraindication to Cabergoline according to the medication prescribing information",{"count":52,"type":22},348,[54],"PHASE2","The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are:\n\nDoes cabergoline decrease the proportion of participants who experience breast symptoms (including breast engorgement, milk leakage, tenderness, and need for pain relief) after abortion or pregnancy loss?\n\nDoes cabergoline reduce the severity of breast symptoms and associated bother compared with placebo?\n\nResearchers will compare participants receiving cabergoline to those receiving placebo to determine whether cabergoline reduces the frequency and severity of breast symptoms following abortion or pregnancy loss.\n\nParticipants will:\n\nComplete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure\n\nReceive a single oral dose of either cabergoline (1 mg) or placebo approximately one hour after the procedure\n\nComplete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother\n\nA subset of participants will provide blood samples at selected time points to measure serum prolactin levels",[57,58],"Pregnancy","Abortion",[60,61],"cabergoline","pregnancy",{"date":34,"type":35},{"date":64,"type":35},"2026-03-16",{"date":66,"type":22},"2028-04",{"name":41,"class":42},""]